Target Validation Information
TTD ID	T35842
Target Name	Melanocortin receptor 1 (MC1R)
Type of Target	Successful
Drug Potency against Target	Ac-dR[CEHdFRWC]-NH2	Drug Info	Ki = 16.78 nM	[1]
	Ac-His-D-Phe-Arg-2-Nal-NHCH3	Drug Info	Ki = 13 nM	[4]
	Ac-His-DPhe-Arg-Trp-NH2	Drug Info	IC50 = 615 nM	[7]
	Ac-Nle-c[Asp-His-DNaI(2')-Pro-Trp-Lys]-NH2	Drug Info	IC50 = 600 nM	[6]
	Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2	Drug Info	IC50 = 1 nM	[6]
	Ac-R[CEHdFRWC]-NH2	Drug Info	Ki = 10.34 nM	[1]
	Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3	Drug Info	Ki = 4520 nM	[4]
	Ac-YCit[CEHdFRWC]-NH2	Drug Info	Ki = 49.42 nM	[1]
	Ac-YK[CEHdFRWC]-NH2	Drug Info	Ki = 15.76 nM	[1]
	Ac-YRC(Me)*EHdFRWC(Me)NH2	Drug Info	Ki = 2.73 nM	[1]
	Ac-YRMEHdFRWG-NH2	Drug Info	Ki = 0.21 nM	[1]
	Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2	Drug Info	Ki = 121.3 nM	[1]
	Ac-YR[CEH(pCl-dF)RWC]-NH2	Drug Info	Ki = 8.22 nM	[1]
	Ac-YR[CEH(pF-dF)RWC]-NH2	Drug Info	Ki = 9.91 nM	[1]
	Ac-YR[CEHdFRWC]-NH2	Drug Info	Ki = 17.12 nM	[1]
	Ac-YR[CEHdFRWC]SPPKD-NH2	Drug Info	Ki = 0.57 nM	[1]
	Ac-YR[CEHFRWC]-NH2	Drug Info	Ki = 147.07 nM	[1]
	Ac-[CEHdFRWC]-NH2	Drug Info	Ki = 67.09 nM	[1]
	AEKKDEGPYRMEHFRWGSPPKD	Drug Info	Ki = 0.89 nM	[1]
	C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2	Drug Info	IC50 = 2000 nM	[5]
	C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2	Drug Info	IC50 = 707 nM	[5]
	C[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2	Drug Info	IC50 = 412 nM	[5]
	C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	Drug Info	IC50 = 410 nM	[5]
	C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2	Drug Info	IC50 = 1500 nM	[3]
	C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2	Drug Info	IC50 = 1400 nM	[3]
	C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2	Drug Info	IC50 = 1000 nM	[3]
	C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2	Drug Info	IC50 = 1000 nM	[3]
	C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2	Drug Info	IC50 = 3000 nM	[3]
	C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2	Drug Info	IC50 = 4000 nM	[3]
	GPYRMEHFRWGSPPKD-NH2	Drug Info	Ki = 0.51 nM	[1]
	MT-II	Drug Info	IC50 = 0.2 nM	[6]
	NDP-SYSMEHFRWGKPVG	Drug Info	Ki = 0.1 nM	[1]
	Tic-D-Phe-Arg-2-Nal-NHCH3	Drug Info	Ki = 2276 nM	[2]
References
REF 1	Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
REF 2	Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1721-5.
REF 3	Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
REF 4	Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73.
REF 5	Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
REF 6	Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35.
REF 7	Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. J Med Chem. 1997 Jul 4;40(14):2133-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.